ConductScience.org, home

Paper7296754

Experimental in vivo cross-resistance of vinca alkaloid drugs.

Maral R and 3 others. Cancer Chemother Pharmacol, 1981. Cited by 29 papers, by iCite.

Cite this record

ConductScience Library. Experimental in vivo cross-resistance of vinca alkaloid drugs. Papers, record 7296754. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7296754

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Experimental in vivo cross-resistance of vinca alkaloid drugs.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1981
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
29
iCite
Relative citation ratio, by iCite
1.5
iCite
Revised in PubMed
2019-08-30
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Maral RR
2Bourut CC
3Chenu EE
4Mathe GG

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Vinca AlkaloidsMajor topic
Animals
Drug Resistance
Leukemia P388
Male
Mice
Vinblastine
Vincristine
Vindesine
Vinorelbine

Source PubMed

Download CSV of topics

References12

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1287569Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/287569PubMed
2445418Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.Cancer Res1979https://conductscience.org/library/papers/445418PubMed
3455579Vindesine. A short review of preclinical and first clinical data.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/455579PubMed
4329987Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).Cancer Treat Rev1977https://conductscience.org/library/papers/329987PubMed
5922743Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia.Cancer Res1977https://conductscience.org/library/papers/922743PubMed
6274996
Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine.
Cancer Treat Rep1978https://conductscience.org/library/papers/274996PubMed
7709555In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.Cancer Treat Rep1978https://conductscience.org/library/papers/709555PubMed
824294903A new class of antitumor compounds: 5'-nor and 5',6'-seco derivatives of vinblastine-type alkaloids.J Org Chem1979https://conductscience.org/library/papers/24294903PubMed
97001942A study of the cross-resistance of vincristine and vindesine in reinduction therapy for acute lymphocytic leukemia in relapse. A report for Children's Cancer Study Group.Am J Pediatr Hematol Oncol1980https://conductscience.org/library/papers/7001942PubMed
106159973Comparative effects of vincristine and vindesine on cell cycle kinetics in vitro.Cancer Treat Rev1980https://conductscience.org/library/papers/6159973PubMed
11412968Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate.J Med Chem1978https://conductscience.org/library/papers/412968PubMed
127387723Cross resistance between actinomycin-D, adriamycin and vincristine in a murine solid tumour in vivo.Biochem Pharmacol1980https://conductscience.org/library/papers/7387723PubMed

Download CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.

PMIDTitleJournalYearIn PapersSource
20809205A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor.Invest New Drugs2012https://conductscience.org/library/papers/20809205PubMed
7803948Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.Drugs Aging1994https://conductscience.org/library/papers/7803948PubMed
7105380Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7105380PubMed
3698163Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3698163PubMed
1742851Pharmacokinetics of navelbine after oral administration in cancer patients.Cancer Chemother Pharmacol1991https://conductscience.org/library/papers/1742851PubMed
1283846Preclinical and clinical pharmacology of vinca alkaloids.Drugs1992https://conductscience.org/library/papers/1283846PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7296754

GET https://conductscience.org/api/papers/v1/7296754/authors